The PD‐1/PD‐L1 axis inhibitors disrupt the interaction between PD‐1 and PD‐L1, subsequently restore immune response toward tumor cells, and finally improve the survival outcomes of cancer patients.4, 59. Here, CD274 is linked to neoplasm.